3,5-Dihydroxyphenyl(Methyl)Phosphinic Acid | 1383535-22-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 3,5-Dihydroxyphenyl(Methyl)Phosphinic Acid
• 英文别名: (3,5-dihydroxyphenyl)-methylphosphinic acid
• CAS: 1383535-22-5
• 化学式: C₇H₉O₄P
• 分子量: 188.12
• InChiKey: KANVIORDKVKQHX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  77.8
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  ethyl (3,5-dimethoxyphenyl)(methyl)phosphinate 在 盐酸 、 三溴化硼 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 20.0h， 生成 3,5-Dihydroxyphenyl(Methyl)Phosphinic Acid
  参考文献：
  名称：

  Identification of Hydroxybenzoic Acids as Selective Lactate Receptor (GPR81) Agonists with Antilipolytic Effects

  摘要：

  Following the characterization of the lactate receptor (GPR81), a focused screening effort afforded 3-hydroxybenzoic acid 1 as a weak agonist of both GPR81 and GPR109a (niacin receptor). An examination of structurally similar arylhydroxy acids led to the identification of 3-chloro-5-hydroxybenzoic acid 2, a selective GPR81 agonist that exhibited favorable in vivo effects on lipolysis in a mouse model of obesity.

  DOI：

  10.1021/ml3000676

文献信息

• Method for identifying a compound useful in mitigating and/or the treatment of a disease associated with abnormal astrocytic function
  申请人：Celica BIOMEDICAL

  公开号：US11231410B2

  公开（公告）日：2022-01-25

  The present invention pertains to a method for identifying a compound that can be used in mitigating and/or the treatment of a disease associated with abnormal astrocytic function, said method comprising: (i) providing a compound; (ii) determining whether said compound is a ligand for the GPR81 receptor by determining said compound's binding energy with the GPR81 receptor using molecular dynamics (MD) simulations and comparing said binding energy to the binding energy determined for a reference compound (such as L-lactate) with the GPR81 receptor; and (iii) if said compound is determined to be a ligand for the GPR81 receptor, bringing said compound in contact with a living astrocyte and determining the cAMP level in said astrocyte contacted with said compound. The present invention further pertains to an agent elevating the cAMP level in astrocytes for use in mitigating and/or in the treatment of a disease associated with abnormal astrocytic function.

  本发明涉及一种确定可用于缓解和/或治疗与星形胶质细胞功能异常有关的疾病的化合物的方法，所述方法包括：(i) 提供化合物；(ii) 利用分子动力学（MD）确定所述化合物与 GPR81 受体的结合能，从而确定所述化合物是否为 GPR81 受体的配体：(i) 提供一种化合物；(ii) 通过使用分子动力学（MD）模拟确定所述化合物与 GPR81 受体的结合能，并将所述结合能与参考化合物（如 L-乳酸盐）与 GPR81 受体的结合能进行比较，从而确定所述化合物是否为 GPR81 受体的配体；和 (iii) 如果确定所述化合物是 GPR81 受体的配体，则使所述化合物与活的星形胶质细胞接触，并确定与所述化合物接触的所述星形胶质细胞中的 cAMP 水平。本发明进一步涉及一种提高星形胶质细胞中 cAMP 水平的制剂，用于减轻和/或治疗与星形胶质细胞功能异常相关的疾病。
• METHOD FOR IDENTIFYING A COMPOUND USEFUL IN MITIGATING AND/OR THE TREATMENT OF A DISEASE ASSOCIATED WITH ABNORMAL ASTROCYTIC FUNCTION
  申请人：Celica BIOMEDICAL

  公开号：EP3341731B1

  公开（公告）日：2020-01-29
• Identification of Hydroxybenzoic Acids as Selective Lactate Receptor (GPR81) Agonists with Antilipolytic Effects
  作者：Curt A. Dvorak、Changlu Liu、Jonathan Shelton、Chester Kuei、Steven W. Sutton、Timothy W. Lovenberg、Nicholas I. Carruthers

  DOI：10.1021/ml3000676

  日期：2012.8.9

  Following the characterization of the lactate receptor (GPR81), a focused screening effort afforded 3-hydroxybenzoic acid 1 as a weak agonist of both GPR81 and GPR109a (niacin receptor). An examination of structurally similar arylhydroxy acids led to the identification of 3-chloro-5-hydroxybenzoic acid 2, a selective GPR81 agonist that exhibited favorable in vivo effects on lipolysis in a mouse model of obesity.